The shortage of semaglutide injections (Ozempic, Wegovy) is over, the FDA announced on Friday. The agency, along with maker Novo Nordisk, confirmed that supply now meets or exceeds both the current ...

We will continue to offer access to personalized treatments as allowed by law to meet patient needs,” Hims & Hers CEO said.

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...

In December, the FDA declared that shortages of treatments Zepbound and Mounjaro from another drugmaker, Eli Lilly and Co., ...

Shares of Hims & Hers Health (NYSE:HIMS) are down about 21%, or $14. All on news the Ozempic shortage is over. Key Points ...

The U.S. Food and Drug Administration declared that the shortage of Novo Nordisk's weight-loss medications Wegovy and Ozempic has been resolved, according to its website. The FDA announcement confirms ...

Though more research is needed to understand who might benefit from GLP-1 agonists for addiction, early studies suggest that the approach holds promise.

The semaglutide shortage has officially ended in the US—which means the GLP-1 drug industry is about to undergo massive changes.

Many of these unlawful and unauthorized shipments were explicitly tagged for compounding, which in turn could put many ...

Conagra and General Mills are among the food companies offering special options for people on GLP-1 drugs, but the products ...

A small percentage of patients taking the extraordinarily popular GLP-1 medications have experienced vision problems ... vision problems while using semaglutide (brand names Wegovy and Ozempic) and ...